X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TPST-1120 is an oral, small molecule, selective PPAR alpha antagonist, can kill tumor cells directly and target suppressive immune pathways in the tumor microenvironment. It is being developed for unresectable or metastatic hepatocellular carcinoma.
Lead Product(s): TPST-1120,Bevacizumab,Atezolizumab
Therapeutic Area: Oncology Product Name: TPST-1120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
TPST-1120 is an oral, small molecule, selective PPAR⍺ antagonist, can kill tumor cells directly and target suppressive immune pathways in the tumor microenvironment. It is being developed for hepatocellular carcinoma.
Lead Product(s): TPST-1120,Bevacizumab,Atezolizumab
Therapeutic Area: Oncology Product Name: TPST-1120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adagene Suzhou Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2023
Details:
TPST-1120 target of PPARα, it is being investigated as a first-line treament of hepatocellular carcinoma, as a monotherapy or in combination with other approved agents.
Lead Product(s): TPST-1120,Bevacizumab,Atezolizumab
Therapeutic Area: Oncology Product Name: TPST-1120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
TPST-1495 is a first-in-class antagonist selective for two receptors in the prostaglandin (PGE2) pathway, EP2 and EP4. Prostaglandins are expressed by advancing tumors and signaling through both EP2 and EP4 drives both tumor growth and immune suppression.
Lead Product(s): TPST-1495,Pembrolizumab
Therapeutic Area: Oncology Product Name: TPST-1495
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
In the monotherapy portion of the trial, 19 patients with late-line treatment-refractory solid tumors, including pancreatic, cholangiocarcinoma (CCA), and colorectal cancers, were treated with oral twice-daily TPST-1120.
Lead Product(s): TPST-1120,Nivolumab
Therapeutic Area: Oncology Product Name: TPST-1120
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
TPST-1120, a first-in-class antagonist selective for peroxisome proliferator-activated receptor alpha, a transcription factor that regulates fatty acid oxidation (FAO) and inflammation and is over-expressed in many cancers.
Lead Product(s): TPST-1120,Nivolumab
Therapeutic Area: Oncology Product Name: TPST-1120
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
TPST-1495 is an orally available small molecule designed to block the cancer-promoting EP2 and EP4 receptors in the prostaglandin (PGE2) pathway, while sparing the homologous but differentially active EP1 and EP3 receptors.
Lead Product(s): TPST-1495,Pembrolizumab
Therapeutic Area: Oncology Product Name: TPST-1495
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
TPST-1495 is an orally available small molecule designed to block the tumor-promoting EP2 and EP4 receptors in the prostaglandin (PGE2) pathway, while sparing the homologous but immune-supporting EP1 and EP3 receptors.
Lead Product(s): TPST-1495,Pembrolizumab
Therapeutic Area: Oncology Product Name: TPST-1495
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
TPST-1495 is an orally-available small molecule designed to block the EP2 and EP4 receptors in the prostaglandin (PGE2) pathway, while sparing the homologous but differentially active EP1 and EP3 receptors.
Lead Product(s): TPST-1495
Therapeutic Area: Oncology Product Name: TPST-1495
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2021
Details:
The merger will facilitate the advancement of our broad pipeline of targeted oncology programs, including TPST-1495 and TPST-1120, which are both progressing in the clinic with encouraging early signs of clinical benefit.
Lead Product(s): TPST-1495
Therapeutic Area: Oncology Product Name: TPST-1495
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Millendo Therapeutics
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Merger March 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
